FASEB Conference-Hematological Malignancies

描述(由申请者提供)：我们请求部分支持美国实验生物学学会联合会(FASE B)将于2005年、2007年和2009年夏季举行的三次“恶性血液病”会议。2005年大会定于2005年7月30日至8月4日在佛蒙特州萨克斯顿河的佛蒙特州学院举行。白血病和淋巴瘤一直是分子靶向癌症治疗的典范，全反式维甲酸治疗急性早幼粒细胞白血病取得了显著成功，格列卫治疗慢性粒细胞白血病、高嗜酸性粒细胞综合征和胃肠道间质瘤取得了显著成功。会议的一个主要焦点将是造血干细胞和癌症干细胞，这将在主旨演讲中得到强调。其他将包括的讨论主题包括：发育性造血；染色体易位产物的作用机制；造血细胞中的正常和病理信号；异常转录调控；细胞周期变化；白血病和淋巴瘤中的凋亡、分化和有丝分裂通路的解除调控；血液系统恶性肿瘤的基因组学；激酶抑制剂和其他实验疗法；以及翻译研究。使用动物模型系统来分析血液癌基因的生物学功能，并作为临床前模型来测试实验药物将是另一个关键课题。这次会议的一个主要目的是将分子生物学家、生物化学家、遗传学家和临床医生聚集在一起。对造血肿瘤发生机制的分析为在不同研究领域拥有专业知识的基础科学家提供了一个独特的机会，让他们与熟悉与各种临床疾病相关的表型的临床医生交流意见。在过去关于这一主题的会议上，交流的信息形成了新的研究途径。因此，拟议中的会议可能会产生治疗血液系统恶性肿瘤的新治疗策略的开发。

DESCRIPTION (provided by applicant): We request partial support for three Federation of American Societies for Experimental Biology (FASEB) conferences on "Hematologic Malignancies" to be held in the summers of 2005, 2007, and 2009. The 2005 conference is scheduled for July 30 - August 4, 2005 at the Vermont Academy in Saxtons River, VT. The leukemias and lymphomas have been the paradigm for molecularly targeted cancer therapy, as illustrated by the remarkable success of all-trans-retinoic acid for the treatment of acute promyelocytic leukemia, and Gleevac for chronic myelogenous leukemia, hypereosinophilic syndrome, and gastrointestinal stromal tumor. A major focus of the conference will be on hematopoietic stem cells and cancer stem cells, which will be highlighted by the keynote address. Among other topics to be included for discussion are: developmental hematopoiesis; mechanisms of action of the products of chromosomal translocations; normal and pathologic signaling in hematopoietic cells; aberrant transcriptional control; cell cycle alterations; deregulation of apoptotic, differentiation and mitogenic pathways in leukemias and lymphomas; genomics of hematological malignancies; kinase inhibitor and other experimental therapeutics; and translational research. The use of animal model systems to analyze the biological functions of hematologic oncogenes and as preclinical models for testing experimental drugs will be another key topic. A major purpose of the meeting is to bring together molecular biologists, biochemists, geneticists, and clinicians. Analysis of the mechanisms underlying the development of hematopoietic neoplasms provides a unique opportunity for basic scientists with expertise in distinct areas of research to exchange ideas with clinicians who are familiar with the phenotypes associated with the various clinical disorders. In past conferences on this topic, new avenues of research have emerged from the information exchanged. Thus, the development of novel therapeutic strategies in the treatment of hematopoietic malignancies is likely to emerge from the proposed meeting.